Navigation Links
Isis Pharmaceuticals Conference Call Notice
Date:6/30/2008

-- Tuesday, July 1, 2008

-- 10:00 a.m. EDT, 7:00 a.m. PDT

-- 877-548-7901

-- http://www.isispharm.com

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals (Nasdaq: ISIS) will conduct a conference call at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, July 1, to discuss results of the TV-1102 clinical trial and the ATL / TEVA / Isis relationship.

-- ATL and TEVA announced clinical data on TV-1102 demonstrating positive disease benefit in patients with multiple sclerosis

-- Isis to received $1.3 million of ATL's $4 million milestone payment from TEVA
-- Isis may receive one third of up to $100 million in milestones

To view the press release

Please visit http://www.isispharm.com or http://www.antisense.com.au/_home.asp to view the release titled:

Teva Pharmaceuticals & Antisense Therapeutics Announce That ATL/TV 1102,

a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis

Demonstrated Significant Reduction in Disease Activity

To access this call via telephone

Please call 1-877-548-7901 in the United States, five to ten minutes prior to the call. You will be asked to provide your name and indicate that you wish to participate in the Isis Pharmaceuticals' conference call hosted by Dr. Stanley Crooke.

To access this call via internet:

Please go to the Isis website at http://www.isispharm.com five to ten minutes prior to the call and click on the Webcast icon on our Home Page.

This webcast will remain posted on Isis' website for a limited time.


'/>"/>
SOURCE Isis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):